Presentation to highlight the Company’s proprietary protein-misfolding platform, EpiSelectTM, used to develop PMN310 Posters highlighting PRECISE-AD, the Company’s Phase 1b clinical trial design and ...

Blood tests could pave the way for distinguishing between Alzheimer’s, Parkinson’s and some dementias, aiding early treatment for brain diseases.

Presentation to highlight the Company's proprietary protein-misfolding platform, EpiSelectTM, used to develop PMN310 Posters highlighting PRECISE-AD, the Company's Phase 1b clinical trial design and ...

Aging-related diseases, including cancer, cardiovascular disorders and type 2 diabetes, are associated with defects in protein synthesis and folding.

One tool, many applications Beyond multiple myeloma, MiROM holds great potential for other diseases linked to protein misfolding, including Alzheimer's and Parkinson's.

Researchers from Helmholtz Munich and the Technical University of Munich have developed a novel method to track cancer treatment responses in individual cells—without the need for dyes or labels.

Pipeline Insight, 2025" report provides a comprehensive analysis of the pipeline landscape with insights on over 3 companies and their emerging drugs in clinical and nonclinical stages for ATTR-CM.

Aging has always been tied hand in hand with the passage of time: a slow and steady process. A little less energy here, a few ...

A University of Massachusetts Amherst researcher has received a five-year, $2 million grant from the National Institutes of ...

Washington DC [US], July 18: A surprising new study has uncovered over 200 misfolded proteins in the brains of aging rats ...